Neoadjuvant Therapy of Pembrolizumab + Ramucirumab for PD-L1 Positive Stage IB-IIIA Lung Cancer (EAST ENERGY)
- Status
- RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Merck Sharp & Dohme LLC
Related studies linked through entity extraction aliases.
A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE2
Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-025)
- Status
- COMPLETED
- Phase
- PHASE3
Ertugliflozin Type 2 Diabetes Mellitus (T2DM) Pediatric Study (MK-8835/PF-04971729) (MK-8835-059)
- Status
- COMPLETED
- Phase
- PHASE3
Event-Related Potential (ERP) Biomarkers in Subjects With Schizophrenia and Healthy Volunteer Subjects
- Status
- COMPLETED
- Phase
- N/A
Establishing the Recommended Biological Dose for AE37 Peptide Vaccine in Combination With Pembrolizumab That Will Enhance the Tumor-specific Immune Response and Demonstrate Efficacy in Patients With Advanced Triple-negative Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Chronic Insomnia and CSF Markers of Dementia
- Status
- COMPLETED
- Phase
- N/A
The Prospective Cohort Study to Evaluate the Preventive Efficacy of HPV Vaccine in Japanese Women Aged 27-45 Years
- Status
- UNKNOWN
- Phase
- N/A
A Study of the Drug Letermovir (LTV) as Prevention for Recurrent of Cytomegalovirus (CMV) Infection
- Status
- COMPLETED
- Phase
- PHASE2
Safety, Tolerability, and Immunogenicity of a 3-dose Regimen of V114 in Healthy Infants (PNEU-PED-EU-2/V114-026)
- Status
- COMPLETED
- Phase
- PHASE3
Pembrolizumab With Ataluren in Patients With Metastatic pMMR and dMMR Colorectal Carcinoma or Metastatic dMMR Endometrial Carcinoma: the ATAPEMBRO Study
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Biomarkers for Neoadjuvant Pembrolizumab in Non-Metastatic Prostate Cancer Positive by 18FDG-PET Scanning
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)
- Status
- COMPLETED
- Phase
- PHASE3
Safety and Pharmacokinetics of Oral Islatravir (MK-8591) Once Monthly in Participants at Low Risk of Human Immunodeficiency Virus 1 (HIV-1) Infection (MK-8591-016)
- Status
- COMPLETED
- Phase
- PHASE2
Efficacy, Immunogenicity and Safety of V503 in Chinese Women Aged 20-45 Years (V503-023)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting Radioactive Agent Works in Combination With Pembrolizumab an Immune Checkpoint Inhibitor in Patients With Stage IV Non-small Cell Lung Cancer With Bone Metastases
- Status
- TERMINATED
- Phase
- PHASE1
Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Pembrolizumab for Patients With PD-L1 Diffuse Large B Cell Lymphoma (DLBCL)
- Status
- TERMINATED
- Phase
- PHASE2
Study of Pembrolizumab in Metastatic HER2-negative Breast Cancer Patients With APOBEC3B Mutation
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype (Keyriched-1)
- Status
- COMPLETED
- Phase
- PHASE2